Clinical Trial Details


Research Study Summary

NAC-MD-01 Hypertension study for patients with stage 1 or stage 2 essential hypertension


The current study will evaluate the efficacy and safety of two anti-hypertensives when given as a fixed dose combination and when given as monotherapy for 8 weeks to hypertensive patients with stage 1 or stage 2 essential hypertension.

Patient Inclusion Criteria:
Female or male 18 year of age and above. Currently being treated for hypertension with at least 1 documented DBP value of >90 and <110 systolic in there medical history or at a recent time during pre screening.
Newly diagnosed with essential hypertension who have never received treatment. Must have a mean sitting DBP >95 and <110 at screening.

Patient Exclusion Criteria:
Secondary hypertension, chronic renal disease, severe HTN. Taking more than 4 antihypertension agents. Coronary artery disease requiring treatment with beta-blockers, calcium channel blockers or chronic nitrates.

To Learn more

CW ID: 181279
Date Last Changed: July 18, 2013

Clinical Trial Snapshot

Both Male and Female
18 and up
Overall Status
Facility Type


Nasra Hashmi, Clinical Research Specialist
Coastal Multi-Specialty Research
2621 S. Bristol St. Suite 108A
Santa Ana, CA 92704
Phone: 714-754-1684

View Map

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.